查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087452

產後憂鬱症治療市場：依治療方法、病患嚴重程度、年齡層、最終用戶和通路分類－2026-2032年全球市場預測

Postpartum Depression Treatment Market by Treatment Type, Patient Severity, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，產後憂鬱症治療市場將成長至 18 億美元，複合年成長率為 7.65%。

主要市場統計數據
基準年 2025 10.7億美元
預計年份：2026年 11.5億美元
預測年份 2032 18億美元
複合年成長率 (%) 7.65%

產後憂鬱症的治療正從間歇性的、帶有污名化的護理轉向系統性的孕產婦心理健康模式，該模式結合了篩檢、心理治療、藥物治療、護理導航和數位化後續觀察。世界衛生組織（世衛組織）已將周產期心理健康問題認定為重大的公共衛生議題。美國疾病管制與預防中心（CDC）報告稱，約八分之一的近期分娩女性會出現產後憂鬱症症狀，凸顯了擴充性且及時的治療途徑的必要性。

目前的治療方案包括實證心理療法，例如認知行為療法和人際關係療法；常用的抗憂鬱症；以及專門針對產後憂鬱症設計的新型神經活性類固醇療法。不斷擴大的孕產婦健康政策、遠距行為醫學的引入，以及人們日益認知到未經治療的產後憂鬱症會影響母親的功能、親子關係、母乳哺育、家庭穩定以及兒童的長期發展，這些因素也都促成了治療需求的成長。

治療環境的變革性變化

產後憂鬱症治療領域最顯著的變化在於，治療模式從一般憂鬱症的管理轉向了針對疾病的個人化治療。美國食品藥物管理局（FDA）分別於2019年和2023年批准了brexanolone和zulanolone，這為產後憂鬱症建立了專門的藥物治療途徑，使人們更加關注那些出現臨床顯著症狀的患者的即時治療方案。

人工智慧（AI）的累積影響

人工智慧（AI）在產後憂鬱症的治療中發揮著日益重要的作用，其應用包括風險分層、症狀監測、提高患者參與度以及支持臨床工作流程。人工智慧工具可以透過分析結構化的醫療記錄、篩檢評分、既往精神病病歷、產科併發症、睡眠模式以及社會健康決定因素來幫助識別高風險患者。然而，這需要模型檢驗，並在臨床醫生的監督下實施。

各區域主要趨勢

由於完善的篩檢指南、FDA批准的療法、私人保險覆蓋、醫療補助計劃的孕產婦健康舉措以及遠距遠端保健的高普及率，北美在產後憂鬱症治療領域仍處於領先地位。隨著特定藥物的核准和產後護理保險覆蓋範圍的改革，美國的創新正在加速推進。同時，加拿大的全民健保體系支持廣泛獲得周產期心理健康服務，但專科醫生等待時間和遍遠地區服務差異仍然是需要克服的挑戰。

關鍵群體特定見解

在東協地區，快速的都市化、行動優先的醫療保健模式以及成員國間心理健康應對能力的不平衡，正在影響產後憂鬱症的治療需求。雖然數位篩檢、護理師主導的諮詢和社區孕產婦保健有助於提高醫療服務的可近性，但要實現永續的實施，還需要語言在地化、消除歧視、建立轉診系統以及進行人力資源發展。

主要國家的概況

美國是產後憂鬱症治療領域商業化程度最高的國家，這得益於美國疾病管制與預防中心（CDC）的監測、美國婦產科醫師學會（ACOG）的篩檢指南、美國食品藥物管理局（FDA）批准的治療方法、遠端醫療的引入，以及許多州擴大憂鬱症醫療補助覆蓋範圍。加拿大商業性重視公共資助的醫療保健和周產期心理健康項目，而墨西哥和巴西則日益需要可擴展的篩檢、遠端醫療、與基層醫療的整合以及低成本的治療方案，以彌合醫療服務取得方面的差距。

為行業領導者提供的實用建議

行業領導者應優先考慮整合產科、小兒科、精神科、基層醫療、藥房服務和數位化後續觀察的綜合護理模式。成功的策略著重於早期篩檢、快速轉診、獲得實證心理治療、藥物安全諮詢、考慮母乳哺育的治療計劃，以及針對嚴重憂鬱症、自殺意念或產後精神病的明確升級路徑。

調查方法

本執行摘要基於檢驗的二手研究以及來自公共衛生機構、監管機構、臨床指南、同行評審文獻和知名醫療機構的多方面檢驗。資訊來源包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、美國食品藥物管理局 (FDA)、美國婦產科衛生署與臨床最佳化研究所 (NICE)、各國衛生部以及已發表的關於憂鬱症的盛行率、篩檢、臨床負擔和治療路徑的研究。

結論

產後憂鬱症的治療正朝著更專業和實證的方向發展，其特點是使用針對特異性疾病的憂鬱症、擴大篩檢、採用遠距遠端醫療、利用人工智慧驅動的工作流程支援以及整合孕產婦心理健康護理。鑑於產後憂鬱症的高發生率、診斷率低以及若不治療會對健康和社會造成顯著影響，其治療效果仍有巨大的提升空間。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 產後憂鬱症治療市場：依治療類型分類

  • 非藥物療法
    • 心理治療
      • 認知行為療法
      • 人際關係療法
    • 神經調控
    • 數位療法
      • 利用行動應用程式進行治療
      • 遠端醫療諮詢
  • 藥物治療
    • 抗憂鬱症
      • SSRI
      • SNRI
    • 荷爾蒙療法
    • 神經活性類固醇療法
      • 布瑞沙諾酮
      • 祖拉諾隆型

第8章：產後憂鬱症治療市場：依患者嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第9章：產後憂鬱症治療市場：依年齡層別分類

  • 25歲以下
  • 25至44歲
  • 44歲或以上

第10章 產後憂鬱症治療市場：依最終使用者分類

  • 醫院
  • 專科診所
  • 心理健康中心
  • 居家照護環境

第11章：產後憂鬱症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 產後憂鬱症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 產後憂鬱症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 產後憂鬱症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • AstraZeneca plc
  • Aurobindo Pharma Ltd
  • Axsome Therapeutics Inc
  • Biogen Inc
  • Brii Biosciences Limited
  • Dr Reddys Laboratories Ltd
  • Eli Lilly and Company
  • GH Research Ireland Limited
  • H. Lundbeck AS
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd
  • Marinus Pharmaceuticals Inc
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sage Therapeutics Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-0372A4B9143E

The Postpartum Depression Treatment Market is projected to grow by USD 1.80 billion at a CAGR of 7.65% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.07 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 1.80 billion
CAGR (%) 7.65%

Postpartum depression treatment is moving from episodic, stigma-constrained care toward a systematic maternal mental health model that combines screening, psychotherapy, pharmacotherapy, care navigation, and digital follow-up. The World Health Organization recognizes perinatal mental health conditions as a major public health concern, and the U.S. CDC reports that approximately 1 in 8 women with a recent live birth experience symptoms of postpartum depression, underscoring the need for scalable and timely treatment pathways.

The treatment landscape includes evidence-based psychotherapies such as cognitive behavioral therapy and interpersonal therapy, commonly used antidepressants, and newer neuroactive steroid therapies designed specifically for postpartum depression. Demand is also being shaped by expanded maternal health policies, telebehavioral health adoption, and greater recognition that untreated postpartum depression can affect maternal functioning, infant bonding, breastfeeding, family stability, and long-term child development.

Transformative Shifts in the Treatment Landscape

The most important shift in postpartum depression treatment is the transition from general depression management to condition-specific care. The U.S. FDA approval of brexanolone in 2019 and zuranolone in 2023 validated a dedicated pharmacological pathway for postpartum depression and increased attention on faster-acting options for patients with clinically significant symptoms.

Health systems are also embedding depression screening into obstetric, pediatric, and primary care visits using validated tools such as the Edinburgh Postnatal Depression Scale and PHQ-9. This is changing treatment demand from one-time medication use toward integrated care models that include diagnosis, referral, therapy access, medication management, lactation-aware counseling, and relapse monitoring during the first year after delivery.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant to postpartum depression treatment through risk stratification, symptom monitoring, patient engagement, and clinical workflow support. AI-enabled tools can help identify patients at higher risk by analyzing structured health records, screening scores, prior psychiatric history, obstetric complications, sleep patterns, and social determinants of health, provided models are validated and deployed with clinician oversight.

The cumulative opportunity is not to replace mental health professionals but to reduce delays in detection and follow-up. AI chat interfaces, remote monitoring, and natural language processing can improve outreach between appointments, but industry leaders must address bias, privacy, informed consent, maternal safety, and escalation protocols for suicidality or psychosis. Verified clinical performance, transparent model governance, and regulatory-grade evidence will be critical differentiators.

Key Regional Insights

North America remains a leading region for postpartum depression treatment adoption due to established screening recommendations, U.S. FDA-approved therapies, commercial insurance coverage, Medicaid maternal health initiatives, and high telehealth penetration. The United States has accelerated innovation through dedicated drug approvals and postpartum coverage reforms, while Canada's universal healthcare framework supports broader access to perinatal mental health services, although specialist wait times and rural access gaps remain challenges.

Europe benefits from national health systems, clinical guidance, and growing investment in perinatal mental health teams, particularly in Western Europe. The European Union's focus on women's health equity, cross-border health data standards, and digital health interoperability is strengthening structured care pathways, while country-level reimbursement, workforce availability, and access to specialist perinatal psychiatry continue to influence uptake.

Asia-Pacific presents a substantial long-term access opportunity because of its birth volume, expanding healthcare infrastructure, and rising public awareness in China, India, Japan, South Korea, and Australia. Latin America is gaining momentum through maternal health programs, primary care expansion, and digital consultation models, but affordability, uneven insurance coverage, and specialist shortages limit consistent treatment access. The Middle East, led by GCC health transformation programs, is improving women's health services and digital care delivery, while Africa faces the most significant treatment gap due to workforce shortages, stigma, limited screening, and insufficient integration of mental health into maternal care.

Key Group Insights

Within ASEAN, postpartum depression treatment demand is shaped by rapid urbanization, mobile-first healthcare behavior, and uneven mental health capacity across member states. Digital screening, nurse-led counseling, and community-based maternal care can improve access, but language localization, stigma reduction, referral capacity, and workforce training are essential for sustainable implementation.

The GCC is advancing maternal health through hospital modernization, women's health initiatives, insurance reforms, and national digital health strategies, creating opportunities for premium clinical programs and culturally adapted telepsychiatry. The European Union is positioned for protocol-driven expansion because of strong public health governance, standardized clinical quality expectations, and women's health policy momentum, although reimbursement, prescribing pathways, and service implementation remain country-specific.

BRICS countries represent a high-volume access opportunity because China, India, Brazil, Russia, and South Africa combine large birth populations with expanding healthcare investment and variable access to psychiatric care. G7 markets lead in regulatory sophistication, clinical research, guideline adoption, pharmacovigilance, and reimbursement experimentation. NATO countries add a distinct focus on military families, where deployment stress, relocation, social isolation, and access continuity can intensify maternal mental health needs and require coordinated postpartum depression treatment pathways.

Key Country Insights

The United States is the most commercially mature postpartum depression treatment environment, supported by CDC surveillance, ACOG screening guidance, U.S. FDA-approved therapies, telehealth adoption, and expanding postpartum Medicaid coverage in many states. Canada emphasizes publicly funded care and perinatal mental health programs, while Mexico and Brazil show growing need for scalable screening, telehealth, primary care integration, and lower-cost treatment options to address access gaps.

In Europe, the United Kingdom benefits from NICE guidance and specialist perinatal mental health services within the NHS. Germany and France have strong healthcare systems, reimbursement infrastructure, and growing attention to maternal mental health, Italy and Spain show rising awareness within maternity and primary care pathways, and Russia presents demand potential but faces regional disparities in mental health access and service availability.

Across Asia-Pacific, China and India represent major volume opportunities due to large birth cohorts, improving maternal health systems, and expanding digital healthcare use. Japan, South Korea, and Australia have more developed clinical infrastructure, with Australia standing out for strong public discussion of perinatal mental health and widely available digital support resources. These markets will reward organizations that combine evidence-based treatment, culturally appropriate engagement, lactation-aware counseling, and postpartum follow-up continuity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated care models that connect obstetrics, pediatrics, psychiatry, primary care, pharmacy services, and digital follow-up. Winning strategies will focus on earlier screening, faster referral, evidence-based psychotherapy access, medication safety counseling, lactation-sensitive treatment decisions, and clear escalation pathways for severe depression, suicidality, or postpartum psychosis.

Pharmaceutical, digital health, and provider organizations should build real-world evidence programs to demonstrate symptom improvement, adherence, maternal functioning, patient-reported outcomes, safety, and health economic value. Partnerships with payers, hospitals, community health workers, lactation consultants, and maternal advocacy organizations can improve trust and reduce dropout. Companies should also invest in culturally adapted education, multilingual support, and privacy-first digital engagement to address stigma, underdiagnosis, and care discontinuity.

Research Methodology

This executive summary is based on verified secondary research and triangulated insights from public health agencies, regulatory bodies, clinical guidelines, peer-reviewed literature, and recognized healthcare organizations. Sources considered include the WHO, CDC, U.S. FDA, ACOG, NICE, national health ministries, and published studies on postpartum depression prevalence, screening, clinical burden, and treatment pathways.

The methodology emphasizes data validity over speculative market claims. Findings were assessed by comparing epidemiology, regulatory milestones, treatment pathways, reimbursement signals, digital health adoption, and regional healthcare capacity. Qualitative insights were structured to support focused executive decision-making while avoiding unsupported market sizing, market share, or forecast-based claims.

Conclusion

Postpartum depression treatment is entering a more specialized, evidence-driven phase shaped by condition-specific medicines, broader screening, telehealth, AI-enabled workflow support, and integrated maternal mental healthcare. The opportunity for improved outcomes is significant because postpartum depression is common, underdiagnosed, and associated with measurable health and social consequences when left untreated.

Future leadership will depend on improving access, affordability, clinical validation, safety monitoring, and continuity of care across the postpartum year. Organizations that combine proven therapies with digital enablement, culturally competent outreach, and rigorous evidence standards will be best positioned to improve outcomes for mothers, infants, and families worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Postpartum Depression Treatment Market, by Treatment Type

  • 7.1. Non-Pharmacological
    • 7.1.1. Psychotherapy
      • 7.1.1.1. Cognitive Behavioral Therapy
      • 7.1.1.2. Interpersonal Therapy
    • 7.1.2. Neuromodulation
    • 7.1.3. Digital Therapeutics
      • 7.1.3.1. Mobile App-based Therapy
      • 7.1.3.2. Telehealth Counseling
  • 7.2. Pharmacological
    • 7.2.1. Antidepressants
      • 7.2.1.1. SSRIs
      • 7.2.1.2. SNRIs
    • 7.2.2. Hormonal Therapy
    • 7.2.3. Neuroactive Steroid Therapy
      • 7.2.3.1. Brexanolone-based
      • 7.2.3.2. Zuranolone-based

8. Postpartum Depression Treatment Market, by Patient Severity

  • 8.1. Mild
  • 8.2. Moderate
  • 8.3. Severe

9. Postpartum Depression Treatment Market, by Age Group

  • 9.1. Below 25 Years
  • 9.2. Between 25 To 44 Years
  • 9.3. Above 44 Years

10. Postpartum Depression Treatment Market, by End User

  • 10.1. Hospitals
  • 10.2. Specialty Clinics
  • 10.3. Mental Health Centers
  • 10.4. Homecare Settings

11. Postpartum Depression Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Postpartum Depression Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Postpartum Depression Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Postpartum Depression Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Acadia Pharmaceuticals Inc
  • 16.3. Amneal Pharmaceuticals LLC
  • 16.4. AstraZeneca plc
  • 16.5. Aurobindo Pharma Ltd
  • 16.6. Axsome Therapeutics Inc
  • 16.7. Biogen Inc
  • 16.8. Brii Biosciences Limited
  • 16.9. Dr Reddys Laboratories Ltd
  • 16.10. Eli Lilly and Company
  • 16.11. GH Research Ireland Limited
  • 16.12. H. Lundbeck AS
  • 16.13. Johnson & Johnson Services, Inc.
  • 16.14. Lupin Ltd
  • 16.15. Marinus Pharmaceuticals Inc
  • 16.16. Merck & Co Inc
  • 16.17. Mitsubishi Tanabe Pharma Corporation
  • 16.18. Novartis AG
  • 16.19. Otsuka Pharmaceutical Co Ltd
  • 16.20. Pfizer Inc
  • 16.21. Sage Therapeutics Inc
  • 16.22. Sanofi SA
  • 16.23. Takeda Pharmaceutical Company Limited
  • 16.24. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SSRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SSRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SSRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SNRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SNRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SNRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HORMONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HORMONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HORMONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BELOW 25 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BELOW 25 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BELOW 25 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 234. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)